Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season
Identifieur interne : 000281 ( PascalFrancis/Checkpoint ); précédent : 000280; suivant : 000282Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season
Auteurs : William Murtaugh [États-Unis] ; Lalla Mahaman [États-Unis] ; Benjamin Healey [États-Unis] ; Heather Peters [États-Unis] ; Barbara Anderson [États-Unis] ; Mandy Tran [États-Unis] ; Marci Ziese [États-Unis] ; Maria Paz Carlos [États-Unis]Source :
- Public health reports : (1974) [ 0033-3549 ] ; 2013.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Santé publique.
English descriptors
- KwdEn :
Abstract
Objectives. We evaluated the implementation of three commericially available neuraminidase inhibition assays in a public health laboratory (PHL) setting. We also described the drug susceptibility patterns of human influenza A and B circulating in Maryland during the 2011-2012 influenza season. Methods. From January to May 2012, 169 influenza virus isolates were tested for phenotypic susceptibility to oseltamivir, zanamivir, and peramivir using NA-Fluor<TM>, NA-Star®, and NA-XTD<TM> concurrently. A 50% neuraminidase inhibitory concentration (IC50) value was calculated to determine drug susceptibility. We used the standard deviation based on the median absolute deviation of the median analysis to determine the potential for reduced drug susceptibility. We evaluated each assay for the use of resources in high- and low-volume testing scenarios. Results. One of the 25 2009 influenza A (H1N1) pandemic isolates tested was resistant to oseltamivir and peramivir, and sensitive to zanamivir, on all three platforms. Eighty-two influenza A (H3N2) and 62 B isolates were sensitive to all three drugs in all three assays. For a low-volume scenario, NA-Star and NA-XTD took 120 minutes to complete, while NA-Fluor required 300 minutes to complete. The lowest relative cost favored NA-Star. In a high-volume scenario, NA-Fluor had the highest throughput. Reagent use was most efficient when maximizing throughput. Cost efficiency from low- to high-volume testing improved the most for NA-Star. Conclusions. Our evaluation showed that both chemiluminescent and fluorescent neuraminidase inhibition assays can be successfully implemented in a PHL setting to screen circulating influenza strains for neuraminidase inhibitor resistance. For improved PHL influenza surveillance, it may be essential to develop guidelines for phenotypic drug-resistance testing that take into consideration a PHL's workload and available resources.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:13-0326981Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season</title><author><name sortKey="Murtaugh, William" sort="Murtaugh, William" uniqKey="Murtaugh W" first="William" last="Murtaugh">William Murtaugh</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Johns Hopkins Bloomberg School of Public Health</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Mahaman, Lalla" sort="Mahaman, Lalla" uniqKey="Mahaman L" first="Lalla" last="Mahaman">Lalla Mahaman</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Healey, Benjamin" sort="Healey, Benjamin" uniqKey="Healey B" first="Benjamin" last="Healey">Benjamin Healey</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Peters, Heather" sort="Peters, Heather" uniqKey="Peters H" first="Heather" last="Peters">Heather Peters</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Anderson, Barbara" sort="Anderson, Barbara" uniqKey="Anderson B" first="Barbara" last="Anderson">Barbara Anderson</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Tran, Mandy" sort="Tran, Mandy" uniqKey="Tran M" first="Mandy" last="Tran">Mandy Tran</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ziese, Marci" sort="Ziese, Marci" uniqKey="Ziese M" first="Marci" last="Ziese">Marci Ziese</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Carlos, Maria Paz" sort="Carlos, Maria Paz" uniqKey="Carlos M" first="Maria Paz" last="Carlos">Maria Paz Carlos</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Johns Hopkins Bloomberg School of Public Health</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">13-0326981</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 13-0326981 INIST</idno><idno type="RBID">Pascal:13-0326981</idno><idno type="wicri:Area/PascalFrancis/Corpus">000216</idno><idno type="wicri:Area/PascalFrancis/Curation">001C11</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000281</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000281</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season</title><author><name sortKey="Murtaugh, William" sort="Murtaugh, William" uniqKey="Murtaugh W" first="William" last="Murtaugh">William Murtaugh</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Johns Hopkins Bloomberg School of Public Health</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Mahaman, Lalla" sort="Mahaman, Lalla" uniqKey="Mahaman L" first="Lalla" last="Mahaman">Lalla Mahaman</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Healey, Benjamin" sort="Healey, Benjamin" uniqKey="Healey B" first="Benjamin" last="Healey">Benjamin Healey</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Peters, Heather" sort="Peters, Heather" uniqKey="Peters H" first="Heather" last="Peters">Heather Peters</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Anderson, Barbara" sort="Anderson, Barbara" uniqKey="Anderson B" first="Barbara" last="Anderson">Barbara Anderson</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Tran, Mandy" sort="Tran, Mandy" uniqKey="Tran M" first="Mandy" last="Tran">Mandy Tran</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ziese, Marci" sort="Ziese, Marci" uniqKey="Ziese M" first="Marci" last="Ziese">Marci Ziese</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Carlos, Maria Paz" sort="Carlos, Maria Paz" uniqKey="Carlos M" first="Maria Paz" last="Carlos">Maria Paz Carlos</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Johns Hopkins Bloomberg School of Public Health</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Public health reports : (1974)</title><title level="j" type="abbreviated">Public health rep. : (1974)</title><idno type="ISSN">0033-3549</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Public health reports : (1974)</title><title level="j" type="abbreviated">Public health rep. : (1974)</title><idno type="ISSN">0033-3549</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Assay</term><term>Evaluation</term><term>Exo-α-sialidase</term><term>Health service</term><term>Influenza</term><term>Laboratory</term><term>Public health</term><term>Season</term><term>Use</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Grippe</term><term>Evaluation</term><term>Exo-α-sialidase</term><term>Dosage</term><term>Utilisation</term><term>Santé publique</term><term>Laboratoire</term><term>Service santé</term><term>Saison</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Santé publique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objectives. We evaluated the implementation of three commericially available neuraminidase inhibition assays in a public health laboratory (PHL) setting. We also described the drug susceptibility patterns of human influenza A and B circulating in Maryland during the 2011-2012 influenza season. Methods. From January to May 2012, 169 influenza virus isolates were tested for phenotypic susceptibility to oseltamivir, zanamivir, and peramivir using NA-Fluor<<sup>TM</sup>>, NA-Star®, and NA-XTD<<sup>TM</sup>> concurrently. A 50% neuraminidase inhibitory concentration (IC<sub>50</sub>) value was calculated to determine drug susceptibility. We used the standard deviation based on the median absolute deviation of the median analysis to determine the potential for reduced drug susceptibility. We evaluated each assay for the use of resources in high- and low-volume testing scenarios. Results. One of the 25 2009 influenza A (H1N1) pandemic isolates tested was resistant to oseltamivir and peramivir, and sensitive to zanamivir, on all three platforms. Eighty-two influenza A (H3N2) and 62 B isolates were sensitive to all three drugs in all three assays. For a low-volume scenario, NA-Star and NA-XTD took 120 minutes to complete, while NA-Fluor required 300 minutes to complete. The lowest relative cost favored NA-Star. In a high-volume scenario, NA-Fluor had the highest throughput. Reagent use was most efficient when maximizing throughput. Cost efficiency from low- to high-volume testing improved the most for NA-Star. Conclusions. Our evaluation showed that both chemiluminescent and fluorescent neuraminidase inhibition assays can be successfully implemented in a PHL setting to screen circulating influenza strains for neuraminidase inhibitor resistance. For improved PHL influenza surveillance, it may be essential to develop guidelines for phenotypic drug-resistance testing that take into consideration a PHL's workload and available resources.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0033-3549</s0></fA01><fA02 i1="01"><s0>PHRPA6</s0></fA02><fA03 i2="1"><s0>Public health rep. : (1974)</s0></fA03><fA05><s2>128</s2></fA05><fA06><s3>SUP2</s3></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season</s1></fA08><fA09 i1="01" i2="1" l="ENG"><s1>Public Health Laboratory Systems: At the Crossroads</s1></fA09><fA11 i1="01" i2="1"><s1>MURTAUGH (William)</s1></fA11><fA11 i1="02" i2="1"><s1>MAHAMAN (Lalla)</s1></fA11><fA11 i1="03" i2="1"><s1>HEALEY (Benjamin)</s1></fA11><fA11 i1="04" i2="1"><s1>PETERS (Heather)</s1></fA11><fA11 i1="05" i2="1"><s1>ANDERSON (Barbara)</s1></fA11><fA11 i1="06" i2="1"><s1>TRAN (Mandy)</s1></fA11><fA11 i1="07" i2="1"><s1>ZIESE (Marci)</s1></fA11><fA11 i1="08" i2="1"><s1>CARLOS (Maria Paz)</s1></fA11><fA12 i1="01" i2="1"><s1>RIDDERHOF (John C.)</s1><s9>ed.</s9></fA12><fA12 i1="02" i2="1"><s1>WILCKE (Burton W.)</s1><s9>ed.</s9></fA12><fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="02"><s1>Johns Hopkins Bloomberg School of Public Health</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></fA14><fA15 i1="01"><s1>Centers for Disease Control and Prevention, Office of Surveillance, Epidemiology and Laboratory Services, Laboratory Science, Policy and Practice Program Office, 1600 Clifton Rd. NE, MS-E94</s1><s2>Atlanta, GA 30333</s2><s3>USA</s3><sZ>1 aut.</sZ></fA15><fA15 i1="02"><s1>Department of Medical Laboratory and Radiation Sciences, College of Nursing and Health Sciences, the University of Vermont at Burlington</s1><s2>Burlington, Vermont</s2><s3>USA</s3><sZ>2 aut.</sZ></fA15><fA20><s1>75-87</s1></fA20><fA21><s1>2013</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>3073</s2><s5>354000501574530110</s5></fA43><fA44><s0>0000</s0><s1>© 2013 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>21 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>13-0326981</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Public health reports : (1974)</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Objectives. We evaluated the implementation of three commericially available neuraminidase inhibition assays in a public health laboratory (PHL) setting. We also described the drug susceptibility patterns of human influenza A and B circulating in Maryland during the 2011-2012 influenza season. Methods. From January to May 2012, 169 influenza virus isolates were tested for phenotypic susceptibility to oseltamivir, zanamivir, and peramivir using NA-Fluor<<sup>TM</sup>>, NA-Star®, and NA-XTD<<sup>TM</sup>> concurrently. A 50% neuraminidase inhibitory concentration (IC<sub>50</sub>) value was calculated to determine drug susceptibility. We used the standard deviation based on the median absolute deviation of the median analysis to determine the potential for reduced drug susceptibility. We evaluated each assay for the use of resources in high- and low-volume testing scenarios. Results. One of the 25 2009 influenza A (H1N1) pandemic isolates tested was resistant to oseltamivir and peramivir, and sensitive to zanamivir, on all three platforms. Eighty-two influenza A (H3N2) and 62 B isolates were sensitive to all three drugs in all three assays. For a low-volume scenario, NA-Star and NA-XTD took 120 minutes to complete, while NA-Fluor required 300 minutes to complete. The lowest relative cost favored NA-Star. In a high-volume scenario, NA-Fluor had the highest throughput. Reagent use was most efficient when maximizing throughput. Cost efficiency from low- to high-volume testing improved the most for NA-Star. Conclusions. Our evaluation showed that both chemiluminescent and fluorescent neuraminidase inhibition assays can be successfully implemented in a PHL setting to screen circulating influenza strains for neuraminidase inhibitor resistance. For improved PHL influenza surveillance, it may be essential to develop guidelines for phenotypic drug-resistance testing that take into consideration a PHL's workload and available resources.</s0></fC01><fC02 i1="01" i2="X"><s0>002B05C02C</s0></fC02><fC02 i1="02" i2="X"><s0>002B30A11</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Grippe</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Influenza</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Gripe</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Evaluation</s0><s5>07</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Evaluation</s0><s5>07</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Evaluación</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Exo-α-sialidase</s0><s2>FE</s2><s5>08</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Exo-α-sialidase</s0><s2>FE</s2><s5>08</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Exo-α-sialidase</s0><s2>FE</s2><s5>08</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Dosage</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Assay</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Dosificación</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Utilisation</s0><s5>13</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Use</s0><s5>13</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Uso</s0><s5>13</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Santé publique</s0><s5>14</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Public health</s0><s5>14</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Salud pública</s0><s5>14</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Laboratoire</s0><s5>15</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Laboratory</s0><s5>15</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Laboratorio</s0><s5>15</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Service santé</s0><s5>16</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Health service</s0><s5>16</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Servicio sanidad</s0><s5>16</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Saison</s0><s5>17</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Season</s0><s5>17</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Estación</s0><s5>17</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Glycosidases</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Glycosidases</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Glycosidases</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Glycosylases</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Glycosylases</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Glycosylases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fN21><s1>308</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Murtaugh, William" sort="Murtaugh, William" uniqKey="Murtaugh W" first="William" last="Murtaugh">William Murtaugh</name></region><name sortKey="Anderson, Barbara" sort="Anderson, Barbara" uniqKey="Anderson B" first="Barbara" last="Anderson">Barbara Anderson</name><name sortKey="Carlos, Maria Paz" sort="Carlos, Maria Paz" uniqKey="Carlos M" first="Maria Paz" last="Carlos">Maria Paz Carlos</name><name sortKey="Carlos, Maria Paz" sort="Carlos, Maria Paz" uniqKey="Carlos M" first="Maria Paz" last="Carlos">Maria Paz Carlos</name><name sortKey="Healey, Benjamin" sort="Healey, Benjamin" uniqKey="Healey B" first="Benjamin" last="Healey">Benjamin Healey</name><name sortKey="Mahaman, Lalla" sort="Mahaman, Lalla" uniqKey="Mahaman L" first="Lalla" last="Mahaman">Lalla Mahaman</name><name sortKey="Murtaugh, William" sort="Murtaugh, William" uniqKey="Murtaugh W" first="William" last="Murtaugh">William Murtaugh</name><name sortKey="Peters, Heather" sort="Peters, Heather" uniqKey="Peters H" first="Heather" last="Peters">Heather Peters</name><name sortKey="Tran, Mandy" sort="Tran, Mandy" uniqKey="Tran M" first="Mandy" last="Tran">Mandy Tran</name><name sortKey="Ziese, Marci" sort="Ziese, Marci" uniqKey="Ziese M" first="Marci" last="Ziese">Marci Ziese</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000281 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000281 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:13-0326981
|texte= Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season
}}
| This area was generated with Dilib version V0.6.34. |  |